Pfizer (PFE) Revenue (2009 - 2026)

Pfizer (PFE) has reported Revenue for 18 consecutive years, with $15.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 2.6% year-over-year to $15.0 billion in Q2 2026; TTM through Jun 2026 was $63.7 billion, a 27.22% decrease from a year earlier, with the FY2025 full-year figure at $62.6 billion, down 1.65% from the prior year.
• Revenue was $15.0 billion for Q2 2026 at Pfizer, up from $14.5 billion in the prior quarter.
• Over five years, Revenue peaked at $45.9 billion in Q3 2024 and troughed at $3.3 billion in Q4 2022.
• A 5-year average of $17.2 billion and a median of $14.9 billion in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue surged 76.78% in 2022 and slumped 63.69% in 2025, its largest moves.
• Over 5 years, Revenue stood at $3.3 billion in 2022, then gained by 5.31% to $3.4 billion in 2023, then soared by 1235.59% to $45.9 billion in 2024, then sank by 61.72% to $17.6 billion in 2025, then slipped by 14.37% to $15.0 billion in 2026.
• The last three Revenue figures came in at $15.0 billion (Q2 2026), $14.5 billion (Q1 2026), and $17.6 billion (Q4 2025), per Business Quant data.